Griseofulvin (ringworm)

Griseofulvin is a fungistatic antifungal antibiotic originally isolated from Penicillium griseofulvum that has been used for over six decades to treat dermatophyte infections in humans and animals. The drug remains one of the most important oral treatments for ringworm in farm animals, offering reliable activity against Trichophyton, Microsporum, and Epidermophyton species that cause superficial fungal infections of the skin, hair, and nails. Despite the development of newer antifungal agents, griseofulvin's proven efficacy and relative safety maintain its place in veterinary therapeutics.

The mechanism of action of griseofulvin involves binding to tubulin proteins in fungal cells, disrupting the formation of the mitotic spindle during cell division. This inhibition of microtubule assembly prevents fungal cell replication, resulting in fungistatic rather than fungicidal activity. The drug concentrates in keratin-containing tissues including skin, hair, and hooves, where it becomes incorporated into newly formed keratin and renders it resistant to fungal invasion.

Griseofulvin is available in several formulations with different particle sizes that affect absorption and dosing requirements. Microsize griseofulvin has particles of approximately 4 micrometers, while ultramicrosize formulations have particles below 1 micrometer. The smaller particles of ultramicrosize preparations provide improved absorption, allowing lower doses to achieve equivalent blood levels. Veterinary formulations are typically microsize powders suitable for incorporation into feed or direct oral administration.

Use of griseofulvin in food-producing animals requires attention to regulatory status, which varies by country. In many jurisdictions, griseofulvin use in food animals is extra-label, necessitating veterinary prescription, documented valid veterinarian-client-patient relationships, and extended withdrawal times. The drug's established efficacy for dermatophytosis and relative safety make it valuable despite regulatory constraints for treating valuable livestock with confirmed ringworm infections.

Bovine ringworm caused primarily by Trichophyton verrucosum represents the most common indication for griseofulvin use in farm animals. This highly contagious dermatophyte infection causes circular areas of hair loss with characteristic gray, crusty lesions, particularly on the head and neck of young cattle. While bovine ringworm is often self-limiting over several months, treatment with griseofulvin accelerates resolution, reduces transmission within herds, and prevents zoonotic spread to humans.

Ringworm in calves deserves particular attention as young animals are most susceptible to infection and suffer the greatest production impacts. Housed calves under intensive management conditions face increased transmission risk due to close contact and shared equipment. Griseofulvin treatment of affected individuals combined with environmental management helps control outbreaks in calf-rearing facilities and prevents establishment of endemic infections.

Sheep and goat dermatophytosis, though less common than bovine ringworm, responds similarly to griseofulvin therapy. Trichophyton verrucosum and Microsporum species can affect small ruminants, causing hair loss and skin lesions that affect animal welfare and fiber quality in wool-producing breeds. Treatment may be indicated for valuable breeding stock or show animals where rapid resolution is desired.

Swine ringworm occurs sporadically and may be caused by Trichophyton or Microsporum species. Clinical signs include circular areas of hair loss with scaling and mild irritation. While economic impact is typically limited in commercial swine production, treatment prevents spread within units and protects human handlers from zoonotic infection.

Equine dermatophytosis, including girth itch caused by Trichophyton equinum and other ringworm presentations, responds to griseofulvin therapy. While horses are not food animals in many countries, their inclusion in farm animal medicine makes griseofulvin therapy relevant for comprehensive dermatophyte management. Draft horses and working equines in agricultural settings benefit from treatment when ringworm affects their ability to work.

Cattle dosing of microsize griseofulvin ranges from 7.5 to 10 mg/kg body weight administered orally once daily. For a 250 kg calf, this represents approximately 2 to 2.5 grams of microsize powder daily. The drug may be mixed with feed, incorporated into a drench, or administered as a paste depending on the formulation available. Ultramicrosize formulations, when available, are used at approximately half the microsize dose due to improved absorption.

Small ruminant dosing follows similar principles, with sheep and goats receiving 7.5 to 10 mg/kg of microsize griseofulvin daily. The smaller body size of these species makes accurate dosing straightforward with veterinary formulations designed for small animal or large animal use. Mixing the daily dose with a small amount of grain ensures consumption and facilitates treatment compliance.

Swine dosing recommendations also center on 7.5 to 10 mg/kg daily for microsize formulations. The drug can be incorporated into feed for group treatment when multiple animals are affected or administered individually for isolated cases. Finisher pigs with ringworm lesions require treatment duration allowing complete replacement of affected skin and hair before marketing.

Absorption of griseofulvin is significantly enhanced when the drug is administered with a high-fat meal. Adding vegetable oil to the dosing vehicle or administering with high-fat feed items increases blood levels and may allow dose reduction. This pharmacokinetic principle should be considered when optimizing treatment protocols for individual animals or herds.

Treatment duration for dermatophytosis typically ranges from 4 to 8 weeks, continuing for at least 2 weeks beyond clinical resolution to ensure elimination of fungal elements from hair follicles and skin. Premature discontinuation commonly leads to relapse as fungal spores remaining in tissues reestablish active infection. Compliance with full treatment courses is essential for successful outcomes.

Withdrawal times for griseofulvin vary by country and are not established in all jurisdictions due to limited residue data. Where guidance exists, meat withdrawal periods typically range from 30 to 56 days after the last treatment. The Food Animal Residue Avoidance Databank provides current recommendations for extra-label use in the United States. Milk from treated dairy animals should not be sold for human consumption during treatment and for extended periods afterward.

Gastrointestinal disturbances are the most commonly reported adverse effects of griseofulvin therapy in farm animals. Decreased appetite, nausea, and diarrhea may occur, particularly at higher doses or when treatment is initiated abruptly. These effects are typically mild and transient, often resolving despite continued treatment. Gradual dose escalation over several days may reduce gastrointestinal intolerance in sensitive individuals.

Photosensitization can occur in animals receiving griseofulvin, manifesting as increased sensitivity to sunlight with erythema and skin damage on non-pigmented areas. White-faced cattle and animals with extensive white markings are at greatest risk. Affected animals should be provided shade and limited sun exposure during treatment. This adverse effect is more commonly reported in small animals but has occurred in livestock.

Hepatotoxicity is a potential concern with griseofulvin, particularly with prolonged treatment courses or in animals with pre-existing liver disease. Signs may include jaundice, elevated liver enzymes, anorexia, and depression. Monitoring liver function during extended treatment helps identify hepatic effects before they become clinically severe. Animals showing signs of hepatotoxicity should have treatment discontinued.

Teratogenic effects have been well documented in laboratory animals and some domestic species receiving griseofulvin during pregnancy. The drug causes developmental abnormalities affecting multiple organ systems when administered during organogenesis. Griseofulvin is contraindicated during pregnancy, and breeding females should not be treated unless absolutely necessary for maternal health.

Hematological abnormalities including leukopenia have been reported with griseofulvin use, particularly in cats and with prolonged treatment. While less commonly documented in farm animals, monitoring of blood counts during extended therapy is prudent. Bone marrow suppression is typically reversible upon treatment discontinuation.

Pregnancy represents an absolute contraindication for griseofulvin use in farm animals. The drug's well-established teratogenicity causes developmental abnormalities including cleft palate, skeletal malformations, and central nervous system defects in multiple species. Pregnant animals should not receive griseofulvin regardless of the severity of their fungal infection. Alternative treatments including topical antifungals should be used in pregnant females.

Intended breeding within the near future is a relative contraindication because of potential effects on germ cells. Males intended for breeding should complete treatment and undergo a waiting period before breeding to allow clearance of the drug and any affected germ cells. Similarly, females should have a treatment-free interval before breeding to ensure drug elimination before conception.

Severe hepatic impairment contraindicates griseofulvin use due to the drug's hepatic metabolism and potential for hepatotoxicity. Animals with known liver disease should receive alternative antifungal therapy rather than risk exacerbating hepatic dysfunction. If treatment is deemed essential, dose reduction and enhanced monitoring are appropriate precautions.

Known hypersensitivity to griseofulvin or related compounds precludes further use. Animals that have experienced allergic reactions during previous griseofulvin treatment should receive alternative antifungal therapy. Cross-reactivity with penicillin-class antibiotics has been suggested due to the drug's origin from Penicillium species, though this remains controversial.

Phenobarbital and other barbiturate anticonvulsants decrease griseofulvin blood levels through induction of hepatic metabolizing enzymes. Animals receiving phenobarbital may require higher griseofulvin doses to achieve therapeutic concentrations. This interaction is clinically relevant for companion animals receiving long-term seizure management but less commonly encountered in farm animal practice.

Warfarin and other coumarin anticoagulants show decreased anticoagulant effect when combined with griseofulvin, likely due to enzyme induction affecting warfarin metabolism. While anticoagulant use in food animals is uncommon, this interaction illustrates griseofulvin's potential to affect metabolism of other medications. Dosage adjustments of anticoagulants may be necessary if concurrent use is required.

Oral contraceptives and hormone preparations may show reduced efficacy during griseofulvin therapy due to enhanced metabolism. This interaction is primarily relevant to human medicine but could theoretically affect hormonal treatments used in livestock reproduction management. Awareness of this potential interaction is appropriate when griseofulvin is used in breeding programs utilizing hormonal manipulation.

Alcohol and other hepatotoxic compounds show potentially additive effects with griseofulvin. While alcohol administration to livestock is uncommon, the principle of avoiding concurrent hepatotoxic exposures applies. Other medications with hepatotoxic potential should be used cautiously during griseofulvin therapy, with enhanced monitoring of liver function.

Zoonotic transmission of dermatophyte infections from animals to humans requires attention during treatment and handling of affected livestock. Ringworm in cattle is readily transmitted to farmers, veterinarians, and others handling infected animals. Protective gloves should be worn when examining or treating affected animals, and hands should be washed thoroughly after contact. Treatment with griseofulvin reduces but does not immediately eliminate the zoonotic risk.

Food safety considerations require strict adherence to withdrawal times and documentation for any griseofulvin use in food-producing animals. Extended meat withdrawal periods are necessary due to the drug's lipophilic nature and tissue accumulation. Milk from treated dairy animals must be discarded during treatment and for extended periods afterward. Complete records of treatment dates, doses, and withdrawal compliance support food safety.

Environmental management complements griseofulvin therapy and is essential for preventing reinfection and spread. Dermatophyte spores persist in the environment for extended periods and recontaminate treated animals if not addressed. Cleaning and disinfection of housing, equipment, and handling facilities using effective fungicidal products should accompany animal treatment.

Sunlight exposure should be limited for animals receiving griseofulvin due to photosensitization potential. Providing shade and avoiding treatment during seasons with intense solar radiation reduces the risk of photosensitivity reactions. Animals with white or non-pigmented skin are at greatest risk and require particular attention.

Monitoring for treatment response guides therapy duration and identifies treatment failures requiring alternative approaches. Hair regrowth in affected areas typically begins within 2 to 3 weeks of effective treatment, with complete resolution over 6 to 12 weeks depending on infection severity. Failure to respond suggests resistant organisms, inadequate dosing, or reinfection from environmental sources.

Griseofulvin powder and tablets should be stored at room temperature between 15°C and 30°C (59°F to 86°F) in tightly closed containers protected from moisture and light. The drug is relatively stable under proper storage conditions, with shelf life typically extending 2 to 3 years from manufacture. Exposure to high humidity can cause caking of powder formulations and reduced accuracy of dosing.

Reconstituted oral suspensions have limited stability and should be stored according to specific product labeling. Many suspensions require refrigeration after preparation and expire within 1 to 2 weeks. Shaking before each use ensures uniform drug distribution throughout the suspension. Expired or improperly stored suspensions should be discarded.

Separate storage from feed and food products prevents contamination that could lead to inadvertent human exposure. The drug's teratogenic potential makes exclusion from areas accessible to pregnant women particularly important. Clear labeling and segregated storage areas maintain safety and prevent accidental exposure. Disposal of expired or unused griseofulvin follows pharmaceutical waste guidelines. The drug should not be disposed of through regular trash or wastewater systems due to potential environmental persistence of antifungal compounds. Return to veterinary clinics for proper disposal or use of pharmaceutical take-back programs ensures appropriate handling.

Cattle breeds show varying susceptibility to ringworm, with housed beef calves of continental European breeding often experiencing higher infection rates than extensively managed breeds. Hereford cattle with white faces may be at increased risk of photosensitization reactions during griseofulvin therapy due to non-pigmented skin. Dairy breeds under intensive housing conditions face increased transmission risk, making treatment more frequently necessary.

Fiber-producing sheep breeds including Merino and other fine-wool types may require more aggressive ringworm treatment to protect fleece quality and value. Dermatophyte infections affecting wool-bearing areas cause permanent fleece damage that persists through subsequent growth cycles. Early treatment limits economic impact on fiber production.

Meat goat and dairy goat breeds may experience ringworm with different clinical presentations and severity. Angora goats with their valuable fiber production warrant treatment attention similar to fine-wool sheep. Dairy goats in intensive housing face transmission risks similar to dairy cattle, requiring herd-level management approaches.

Show and breeding stock across all species often receive griseofulvin treatment to rapidly resolve ringworm lesions that would affect sale value or show appearance. The cosmetic impact of ringworm on these valuable animals justifies treatment costs and withdrawal period considerations. However, pregnancy status must be confirmed before treating breeding females due to teratogenicity concerns.

Terbinafine is an allylamine antifungal with excellent activity against dermatophytes that serves as an alternative to griseofulvin. The drug offers fungicidal rather than fungistatic activity and may provide more rapid clinical resolution. Terbinafine has been used in various animal species but has limited regulatory approval and established dosing for farm animals, restricting its practical use in livestock.

Topical antifungal preparations including miconazole, clotrimazole, and enilconazole provide local treatment options for ringworm that may be used alone for limited lesions or in combination with systemic griseofulvin for extensive infections. Topical treatments avoid systemic exposure and withdrawal concerns but are impractical for treating large numbers of animals or lesions in difficult-to-reach locations.

Itraconazole and fluconazole offer azole antifungal alternatives with activity against dermatophytes, though neither is specifically indicated for ringworm treatment in most species. These agents may be considered when griseofulvin is contraindicated or ineffective, though limited veterinary experience and cost considerations restrict their use for dermatophytosis in food animals.